Physician profile
Arshad Javed
NPI 1588950075
$3,750.40
in general payments reported to CMS, 2019-2025
26 companies · $696 in 2025
The $696 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $23.09 · 2021: $177 · 2022: $483 · 2023: $1,111 · 2024: $694 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,491.65 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $573.70 | 2022-2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $526.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $426.61 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $395.67 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.67 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $336.45 | 2022-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $299.25 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $174.90 | 2022-2024 | Farxiga |
| Edwards Lifesciences Corporation | $141.51 | 2019-2020 | |
| Heartflow, INC. | $120.47 | 2024 | |
| Amgen INC. | $57.99 | 2019-2022 | |
| Boston Scientific Corporation | $45.10 | 2021-2024 | Watchman Flx |
| Lundbeck LLC | $40.50 | 2019 | |
| Pfizer INC. | $33.22 | 2019-2022 | |
| Novo Nordisk INC | $31.46 | 2021-2023 | Rybelsus, Ozempic |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $29.00 | 2023 | |
| Chiesi USA, INC. | $22.61 | 2024 | Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $21.02 | 2025 | |
| Abiomed | $20.62 | 2025 | |
| Amarin Pharma, INC. | $19.38 | 2021 | |
| Inspire Medical Systems, INC. | $17.78 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $16.02 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $15.72 | 2022 | |
| Astellas Pharma US INC | $15.55 | 2019 | |
| Scpharmaceuticals INC. | $14.49 | 2024 | |
| Sanofi-Aventis U.S. LLC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.